A Phase III trial found that adding Sanofi's diabetes drug candidate Lyxumia to basal insulin improved body mass and blood glucose level while not heightening the risk of hypoglycemia in patients with type 2 diabetes. Lyxumia, a GLP-1 agonist licensed from Zealand Pharma, would compete against Victoza and Amylin from Novo Nordisk and Byetta from Eli Lilly and Co.

Full Story:
Reuters, Fox Business

Related Summaries